|
Blake Aftab PhD
Chief Scientific Officer
Adicet Bio, Inc.
USA
|
Dr. Aftab is the Chief Scientific Officer at Adicet Bio leading the design and development of first-in-class allogeneic gamma-delta CAR T cell therapies. Dr. Aftab has nearly 20 years of rich experience in academia, biotech and pharmaceutical industries developing multiple therapeutic modalities including small molecules, biologics, antibody-drug conjugates and cell therapies through all stages drug development, including three approved therapies across small molecule, antibody, and allogeneic T cell platforms. Dr. Aftab previously served as Vice President and Head of Preclinical Science and Translational Medicine at Atara Biotherapeutics, Inc., where he contributed to the company’s initial transition to cell therapy, culminating in the first ever regulatory approval of an allogeneic T cell therapy, and later led the focus on developing Allo-CAR T cell capabilities. Previously, Dr. Aftab led multiple research programs at University of California, San Francisco focused on drug discovery and clinical translation in multiple myeloma, including early research supporting targeted approaches for CD38 and other impactful targets of interest for CAR-T therapies. Dr. Aftab received his Ph.D. from The Johns Hopkins University School of Medicine and holds a B.Sc. in Pharmacology and Drug Discovery, from The University of California, Santa Barbara.